SCHEMBL4459609

SCHEMBL4459609

OB(O)c1cccc(OCC(COCc2ccccc2)OCc2ccccc2)c1F

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LIPE Q05469 2/20 0.48
ENPP2 Q13822 1/20 0.39
MAPT P10636 1/20 0.38
MAPK1 P28482 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
SLC6A9 P48067 1/20 0.36
SLC6A5 Q9Y345 1/20 0.36
CA1 P00915 4/20 0.36
CA2 P00918 2/20 0.36
CA7 P43166 2/20 0.36
CA9 Q16790 2/20 0.36
PPARD Q03181 1/20 0.36
KMT2A Q03164 2/20 0.35
MEN1 O00255 1/20 0.35
TP53 P04637 1/20 0.35
GAA P10253 1/20 0.35
PLA2G10 O15496 1/20 0.35
PLA2G2A P14555 1/20 0.35
HTR1A P08908 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2157681 0.80 LIPE (0.73) LIPEENPP2MAPTMAPK1TDP1
SCHEMBL177451 0.80 PPARD (0.39) LIPECA1CA2CA7CA9
SCHEMBL177450 0.80 PPARD (0.39) LIPECA1CA2CA7CA9
SCHEMBL4535810 0.74 TSHR (0.58) MAPK1CA1CA2CA7CA9
SCHEMBL29955137 0.73 LIPE (0.40) LIPEENPP2MAPTGAASLC6A4
SCHEMBL4459615 0.72 MEN1 (0.38) LIPEMAPK1CA1CA2CA7
SCHEMBL12030976 0.71 MRGPRX4 (0.47) TDP1L3MBTL1CA1CA2CA7
SCHEMBL9575753 0.70 TSHR (0.52) MAPK1CA1CA2CA7CA9
SCHEMBL16016783 0.69 PLA2G10 (0.45) MAPTMAPK1TDP1CA1PPARD
SCHEMBL2560139 0.69 LIPE (0.63) LIPEENPP2MAPTMAPK1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8629125-B2 Inhibitors of fatty acid amide hydrolase Infinty Pharmaceuticals, Inc. (US) 2014-01-14 US disclosed
US-20130059819-A1 INHIBITORS OF FATTY ACID AMIDE HYDROLASE INFINITY PHARMACEUTICALS, INC. (US) 2013-03-07 US disclosed
EP-2073816-A2 INHIBITORS OF FATTY ACID AMIDE HYDROLASE Infinity Pharmaceuticals, Inc. (US) 2009-07-01 EP disclosed
WO-2008063300-A2 BORONIC ACIDS AND ESTERS AS INHIBITORS OF FATTY ACID AMIDE HYDROLASE INFINITY PHARMACEUTICALS, INC. (US) 2008-05-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130059819-A1 INHIBITORS OF FATTY ACID AMIDE HYDROLASE FAAH, FAAH2, ASAH1 LIPE 88/4885ENPP2 36/4885MAPT 2853/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.